About xilio therapeutics inc - XLO
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of tumor-activated immuno-oncology therapies for the treatment of cancer. The firm uses its Geographically Precise Solutions (GPS) platform to develop tumor-activated molecules, including cytokines, antibodies and other biologics. The company was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
XLO At a Glance
Xilio Therapeutics, Inc.
828 Winter Street
Waltham, Massachusetts 02451
| Phone | 1-857-524-2466 | Revenue | 43.77M | |
| Industry | Pharmaceuticals: Major | Net Income | -35,036,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 589.88% | |
| Fiscal Year-end | 12 / 2026 | Employees | 76 | |
| View SEC Filings |
XLO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.712 |
| Price to Book Ratio | 1.151 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.376 |
| Enterprise Value to Sales | -1.272 |
| Total Debt to Enterprise Value | -0.125 |
XLO Efficiency
| Revenue/Employee | 575,868.421 |
| Income Per Employee | -461,000.00 |
| Receivables Turnover | 8.753 |
| Total Asset Turnover | 0.384 |
XLO Liquidity
| Current Ratio | 2.577 |
| Quick Ratio | 2.577 |
| Cash Ratio | 2.444 |
XLO Profitability
| Gross Margin | 96.479 |
| Operating Margin | -95.924 |
| Pretax Margin | -80.053 |
| Net Margin | -80.053 |
| Return on Assets | -30.765 |
| Return on Equity | -132.534 |
| Return on Total Capital | -82.971 |
| Return on Invested Capital | -107.085 |
XLO Capital Structure
| Total Debt to Total Equity | 19.715 |
| Total Debt to Total Capital | 16.468 |
| Total Debt to Total Assets | 4.438 |
| Long-Term Debt to Equity | 15.907 |
| Long-Term Debt to Total Capital | 13.288 |